ImmunityBio Inc (NASDAQ:IBRX) currently has a daily average trading volume of 7.82M but it saw 9684463 shares traded in last market. With a market cap of 2.34B USD, the company’s current market price of $2.65 came falling about -8.62 while comparing to the previous closing price of $2.90. In past 52 weeks, the stock remained buoying in the range of price level as high as $7.63 and as low as $1.83.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Piper Sandler which upgraded the stock as “Overweight” in its note to investors issued on May 20, 2025, recommending a price target of $5 for it. BTIG Research issued its recommendations for the stock as it initiated the price target for the stock is $6.
Over the week, IBRX’s stock price is moving 6.43% up while it is -1.49% when we observe its performance for the past one month. Year-to-date it is 3.52% up and over the past year, the stock is showing a downside performance of -65.36%.
The company is expected to be releasing its next quarterly report in June, for which analysts forecasted an EPS of -0.1 while estimate for next year EPS is -0.5. In next quarter, company is expected to be making quarterly sales of $27.85M as analysts are expecting the sales for current fiscal year at $99.35M and seeing the company making $228.32M in sales next year. Moreover, analysts are in estimates of $21.95M for current-quarter revenue.
Currently, ImmunityBio Inc’s total number of outstanding shares is 853.39M with 74.11% of that held by the insiders while 9.23% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -182.90%. Stock’s beta reads 0.02. Stock has a price to sale or P/S ratio amounts to 74.92. Its return on asset (ROA) is -116.15% on average.
